Clinical trial
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
NCT05171972
Study timeline
Study start (actual)2022-01-29Date precision: day
Registry last updated2026-05-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Relapsing Remitting Multiple Sclerosisunresolved
Interventions
OfatumumabDRUG · verified · RxNorm: ofatumumab
Sponsors & collaborators
University of Southern Californialead sponsor
Novartis Pharmaceuticalscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05171972 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.